Backes, Carl H.
Notestine, Jennifer L.
Lamp, Jane M.
Balough, Jeanne C.
Notestine, Allison M.
Alfred, Crystal M.
Kern, Juli M.
Stenger, Michael R.
Rivera, Brian K.
Moallem, Mohannad
Miller, Randy R.
Naik, Apurwa
Cooper, Jennifer N.
Howard, Christopher R.
Welty, Stephen E.
Hillman, Noah H.
Zupancic, John A. F.
Stanberry, Larissa I.
Hansen, Thomas N.
Smith, Charles V.
Funding for this research was provided by:
Bill and Melinda Gates Foundation (OPP1094124, OPP1094124)
Article History
Received: 1 November 2018
Accepted: 24 December 2018
First Online: 18 January 2019
Ethics approval and consent to participate
: The IRB of NCH approved the trial (16–00678). The IRB at Mt. Carmel St. Ann’s Hospital granted separate approval for the trial (170817–2).
: Not applicable.
: TNH and CVS are included among the holders of patents on the Seattle-PAP device, specifically United States Patent 8499759, under the title “Broad-band, low frequency, high-amplitude, long time duration, oscillating airway pressure breathing apparatus and method utilizing bubbles.” This listing is readily available on-line. The patent is also registered with the World Intellectual Property Organization (PCT/US2009/039957), with patents or letters granted in several regions or countries, including Europe (2303373), Korea (10–1,540,948), New Zealand (588682), China (201310269076.X), Canada (2720976), Vietnam (13756), and India (7898/DELNP/2010). A patent has also been issued in Australia (2010241205) under a modified name. The patent holders are committed to the Global Access Policy (ExternalRef removed) of the Bill & Melinda Gates Foundation. The rights to the Seattle-PAP device have been licensed to Draeger, which will have no role in the study. The remaining authors have no potentially competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.